S.

S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ -- - New Option for Treatment of Epilepsy Patients With Partial Onset Seizures Bial-Portela & CA, S.A., (S.

LONDON, February 19 /PRNewswire-FirstCall/ -- - Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd.

PORTO, Portugal, December 8 /PRNewswire/ -- - Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate) Positive data from three phase III studies presented today at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM)(1) (eslicarbazepine acetate), a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures and has the potential to significantly improve quality of life and depressive symptoms in patients with partial refractory epilepsy, in combination with other anti-epileptic agents.(2),(3),(4) Zebinix(TM) is one of the proposed EU trade names for eslicarbazepine acetate. Zebinix(TM) 800mg and 1200mg once-daily significantly reduced the frequency of partial seizures by over one third during the 12 week maintenance period of the studies.(5),(6),(7),(8) In addition, new data presented for the first time at AES

BANGALORE: The government has set up a joint legislature committee to look into allegations that Bengaluru International Airport (BIA) is not a world-class airport.